The appraisal was discussed by the technology appraisal committee on 13 July 2021.
The Committee for Medicinal Products for Human Use (CHMP) has not yet given its opinion on lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. We are therefore unable to release the committee’s recommendation.